Beijing Immunochina Medical Science & Technology Co., Ltd.
Quick facts
Phase 1 pipeline
- AMT-116 CAR-T cells
- AMT-253 CAR-T cells
- anti-GPC3 CAR-T cells
- Decitabine and R-GDP
- IM19
- IM19 CAR-T
- IM19 CAR-T cells
- IM23
- IM83 CAR-T Cells
- IM92 CAR-T cells
- IM96 CAR-T Cells
- INS19 CAR-T Cells
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: